QUANTITATIVE/SEMI-QUANTITATIVE MEASUREMENT OF EPOR ON CANCER CELLS

摘要

The present invention provides for assays useful in predicting whether a cancer patient risks suffering erythropoietin-induced tumor progression if treated with erythropoietin. More specifically, one embodiment provides for a validated quantitative reverse transcriptase polymerase chain reaction assay that detects erythropoietin receptor expression, thus indicating whether a cancer patient risks suffering erythropoietin-induced tumor progression if treated with erythropoietin.